Halobetasol propionate cream by day and halobetasol propionate ointment at night for the treatment of pediatric patients with chronic, localized plaque psoriasis and atopic dermatitis.

Abstract

In a multicenter, 14-day pediatric study in 81 evaluable patients with severe, localized corticosteroid-susceptible dermatoses, the combined treatment with halobetasol propionate cream once during the day and halobetasol propionate ointment once at night produced a very satisfactory therapeutic effect. The success rates, as indicated by ratings of "healed" and "marked improvement," were 100% and 90.9% in patients with atopic dermatitis and psoriasis vulgaris, respectively. Healing was reported in 86.8% and 72.7% of patients treated for atopic dermatitis and psoriasis, respectively. Both the cream and ointment preparations were well tolerated. Adverse effects at the site of application were reported in only 3 of 81 patients. Mild skin atrophy was observed in one patient. No systemic adverse effects were observed.

• Authors: G Herz, G Blum, S Yawalkar
• Journal: Journal of the American Academy of Dermatology (J Am Acad Dermatol) Vol. 25 Issue 6 Pt 2 Pg. 1166-9 (Dec 1991) ISSN: 0190-9622 [Print] United States
• PMID: 1757611 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)

Chemical References

• Ointments
• Vasoconstrictor Agents
• halobetasol
• Clobetasol

Topics

• Administration, Cutaneous
• Adolescent
• Child
• Child, Preschool
• Chronic Disease
• Clobetasol (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
• Dermatitis, Atopic (drug therapy)
• Drug Tolerance
• Female
• Humans
• Male
• Ointments
• Psoriasis (drug therapy)
• Remission Induction
• Switzerland
• Vasoconstrictor Agents (administration & dosage, adverse effects, therapeutic use)
• Wound Healing